Skip Ribbon Commands
Skip to main content
Navigate Up
Sign In
 
 

 Latest News

 
1/6/2015
Pharmerit conducted an analysis to estimate the incremental cost-effectiveness of hexaminolevulinate for patients diagnosed with non-muscle invasive bladder cancer (NMIBC) in Italy
12/15/2014
Despite its rarity, anal cancer places a significant economic burden on the public purse and moreover resource pressures on the national health service.
11/19/2014
We have enjoyed meeting you at the 17th European ISPOR conference in Amsterdam, November 2014. Hand-outs of the poster sessions are available on our ISPOR Amsterdam event page.
10/7/2014
​Meet our team of experts at the ISOQOL 21st Annual Conference in Berlin, 15-18 October, 2014. We invite you to our exhibit, presentations, and workshop.
9/19/2014
On September 18, 2014, Pharmerit and IPAM jointly hosted a successful workshop in Berlin.
6/23/2014
Adalimumab is cost effective in treating Spanish patients with non-radiographic axial spondyloarthritis and elevated CRP and/or positive MRI.
6/12/2014
In the first study examining pHF-W vs. CMF in an Asian country, Pharmerit, Nestlé Nutrition and affiliates found pHF-W to be a cost effective alternative for atopic dermatitis.
5/15/2014
Guideline-recommended treatments for PHN are more effective vs. placebo. Additional evaluations for less common NeP conditions are required, despite published treatment guidelines.
4/28/2014
Anastomotic leaks—one of the surgical complications following colorectal surgeries—are associated with significant economic burden in the United States, including significantly extended hospital stays and excess medical costs.
4/15/2014
The risks of BSIs vary according to the type of parental nutrition provided. The safest approach, consisting of ready-to-use three-chamber bag (MCB), was also shown to be essentially cost neutral.
Contact Feel free to contact us if you have any questions